Archive for the Official Press Releases Category
Lumos Pharma Raises $34 Million in Series B Financing
AUSTIN, Texas – April 6, 2016 – Lumos Pharma, a biotechnology company focused on developing therapeutics for orphan diseases, announced the successful completion of a $34 million Series B financing. Lumos will use the proceeds for clinical trials and commercialization of its lead compound, LUM-001, for the treatment of Creatine Transporter Deficiency (CTD). Funding will...Read More
Lumos Pharma Announces Series A Financing
AUSTIN, Texas – February 4th, 2014 – Lumos Pharma, an early stage biopharmaceutical development company, announced today that it has raised $14 million in Series A financing. The round was co-led by Santé Ventures and New Enterprise Associates (NEA). Lumos Pharma will use the financing to support the preclinical and clinical development of its lead...Read More
Lumos Pharma Receives Wellcome Trust Award for Advancing Potental Treatment of Creatine Transporter Deficiency (CTD)
AUSTIN, Texas – May 4th, 2015 – Lumos Pharma, Inc. (Austin, Texas) announced today that it has received an award of up to $5.5 million from the Translation Fund of the Wellcome Trust. CEO of Lumos Pharma, Richard Hawkins, stated “We are very pleased Wellcome Trust has selected Lumos for an award and we are privileged...Read More